Sodium Bicarbonate in Cardiopulmonary Resuscitation (SB CAT)
Recruitment status was: Not yet recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Out-of-hospital cardiac arrests (OHCA) account for over 60% of deaths from coronary artery disease. The annual incidence of OHCA treated by Emergency Medical Systems (EMS) is 41-89 per 100,000 population. Outcome of OHCA and cardiopulmonary resuscitation (CPR) is very poor: Less than 1/3 of the victims regain spontaneous circulation (ROSC), 40-60% of those achieving ROSC suffer significant neurological disability due to brain hypoxia and only 1.7-6.4% are discharged from the hospital. In order to minimize hypoxia time, the primary goal of CPR is to achieve return of spontaneous circulation (ROSC) as fast as possible. Metabolic (lactic) acidosis develops rapidly during CA and is considered detrimental to CPR outcome. Sodium bicarbonate (SB), a generic, commonly used acid buffer, was subjected only to a single, small, prospective controlled trial that found a trend towards improved outcome in prolonged OHCA and CPR. Another study indicated that EMS's that used SB early and often during CPR had significantly higher ROSC rates and better long-term outcome compared with EMS's that used SB more seldom and administered it late in the course of CPR.
Aim of the Study:
To determine whether early administration of SB during OHCA and CPR improves short-term CPR outcome.
| Condition | Intervention | Phase |
|---|---|---|
| Sudden Cardiac Arrest | Drug: sodium bicarbonate | Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Does the Early Use of Sodium Bicarbonate Improve Results of Cardiopulmonary Resuscitation Following Out-of-Hospital Cardiac Arrest - a Prospective, Controlled Clinical Trial |
- Short-term survival [ Time Frame: at completion of CPR ]proportion of patients who achieve return of spontaneous circulation (ROSC) and proportion of patients admitted alive (not requiring CPR) to the hospital's emergency room
| Estimated Enrollment: | 2130 |
| Study Start Date: | December 2011 |
| Estimated Study Completion Date: | March 2014 |
| Estimated Primary Completion Date: | December 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: Sodium bicarbonate
1 mEq/kg sodium bicarbonate administered intravenously immediately following the administration of the first epinephrine dose during advanced CPR.
|
Drug: sodium bicarbonate
1 mEq/kg sodium bicarbonate administered intravenously immediately following the administration of the first epinephrine dose during advanced CPR. Dose may be repeated every 5-10 minutes up to 3 doses. Note: The Placebo Arm receives 1 ml/Kg of 0.9% NaCl (in a blinded fashion). |
|
Placebo Comparator: 0.9% NaCl
1 ml/kg of 0.9% NaCl (Blinded label)
|
Drug: sodium bicarbonate
1 mEq/kg sodium bicarbonate administered intravenously immediately following the administration of the first epinephrine dose during advanced CPR. Dose may be repeated every 5-10 minutes up to 3 doses. Note: The Placebo Arm receives 1 ml/Kg of 0.9% NaCl (in a blinded fashion). |
Detailed Description:
General: Prospective, randomized, double blinded, placebo-controlled clinical trial. Exception from Informed Consent, under the regulations for the conduction of research in emergency situations, has been approved by the Helsinki Committee of the Rambam Medical Center and by the Supreme Helsinki Committee of the Israeli Ministry of Health. Included will be adult patients who suffer an OHCA, who do not respond to basic CPR and to early defibrillation and in whom advanced CPR is initiated. 1st dose (1 mEq/Kg) of SB/placebo will be administered by Israeli Magen David Adom (MDA) advanced life support (ALS) teams immediately following the first IV epinephrine. SB/placebo vials or syringes will be masked and coded. Calculated sample size is 2130 patients. Study endpoints include only short-term outcome variables - rates of ROSC and of admission to the emergency room.
Expected results: Based on previous analysis we expect a 20% improved short-term outcome in the SB treated group. Sample size was calculated accordingly.
Importance: Around 2.2 million OHCA's are treated by EMS worldwide annually. Current ROSC rate is ca. 30%. A 20% better short-term outcome will result in over 130,000 additional patients regaining spontaneous circulation annually.
Probable implications to Medicine: The use of SB in CPR is controversial. Current International Guidelines for CPR present very reserved recommendations regarding SB use. Results of this study may have a direct impact on the Guidelines and on the conduction of CPR world-wide. Based on the results of this trial, a Phase II trial, researching the effects of early SB administration on long-term outcome (hospital discharge and final neurological outcome) may be warranted and conducted.
Eligibility
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- patients who suffer Out of hospital, non-traumatic cardiac arrest
- patients who do not respond to the initial resuscitation efforts (including basic CPR, defibrillation (when indicated) and other appropriate ACLS measures)
- patients in whom a vascular access (either an IV line or an intraosseous needle) has been obtained
- patients who have reached the "drugs" step in the ACLS algorithm.
Exclusion Criteria:
- Patients with known terminal illness
- Patients with a Do Not Resuscitate (or similar) order
- Cardiac arrest due to trauma, drug overdose or known intracranial disease
- Age less than 18 years
- Known pregnancy
- Patients in whom 30 minutes or more have passed from collapse to initiation of CPR
- If collapse time is unknown - patients with obvious death marks
- Patients with no vascular access (either an IV line or an intraosseous needle)
Contacts and Locations
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01377337
| Contact: Gad Bar-Joseph, Prof. | 972-50-2062115 | g_barjoseph@rambam.health.gov.il | |
| Contact: Rachel Gil, RN | 972-50-2064257 | r_gil@rambam.health.gov.il |
| Israel | |
| Rambam Medical Center | Not yet recruiting |
| Haifa, Israel, 31096 | |
| Contact: Gad Bar-Joseph, Prof. g_barjoseph@rambam.health.gov.il | |
| Magen David Adom | Not yet recruiting |
| Tel Aviv, Israel | |
| Contact: Zvi Figenberg, MD zvif@mdais.co.il | |
| Principal Investigator: | Gad Bar-Joseph | Rambam Health Care Campus |
More Information
| Responsible Party: | Rambam Health Care Campus |
| ClinicalTrials.gov Identifier: | NCT01377337 History of Changes |
| Other Study ID Numbers: |
0013-09-RMB |
| First Submitted: | June 16, 2011 |
| First Posted: | June 21, 2011 |
| Last Update Posted: | November 8, 2011 |
| Last Verified: | November 2011 |
Keywords provided by Rambam Health Care Campus:
|
cardiac arrest cardiopulmonary resuscitation (sodium) bicarbonate return of spontaneous circulation outcome |
Additional relevant MeSH terms:
|
Heart Arrest Out-of-Hospital Cardiac Arrest Death, Sudden, Cardiac Heart Diseases |
Cardiovascular Diseases Death, Sudden Death Pathologic Processes |